Tuğba Bozdemir

Dr. Tuğba Bozdemir


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2026 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
DTDemet Timur
Demet Timur
EGEmel Gürcüoğlu
Emel Gürcüoğlu
EÖEmre Özkarataş
Emre Özkarataş
TBTuğba Bozdemir
Tuğba Bozdemir
Local species distribution and antifungal susceptibility are important for empirical candidemia management. We retrospectively evaluated patients with Candida-positive blood cultures from August 2019 to May 2024. Episodes were defined using a 30-day window; species distribution and susceptibility were analysed at the episode–species level and outcomes at the patient level. Among 566 patients, 605 episodes and 637 episode–species isolates were identified. Non-albicans Candida accounted for 59.7%; C. albicans (40.3%) and C. parapsilosis (34.2%) predominated. Of 217 C. parapsilosis isolates tested, 66 (30.4%) were fluconazole-susceptible, 58 (26.7%) were susceptible dose-dependent, and 93 (42.9%) were resistant. Recurrent candidemia occurred in 37 patients and documented microbiological persistence in 128 (22.6%); persistence was more frequent when the index culture included C. parapsilosis (27.6% vs. 20.1%; OR 1.52, 95% CI 1.01–2.28). Among 32 patients with a shared species in the initial and first recurrent episodes, newly detected resistance occurred in three, all involving fluconazole-resistant C. parapsilosis. Thirty-day all-cause mortality was 57.4%; older age, ICU care, mechanical ventilation, and solid malignancy were independently associated with higher mortality. These findings suggest that empirical reliance on fluconazole may be inappropriate in settings with similar resistance patterns and support species-level identification, repeat blood cultures, and episode-specific susceptibility testing.